Who owns Amphastar Pharmaceuticals, Inc. (AMPH)? Elite investor 13F holders
4 tracked elite investors reported holding Amphastar Pharmaceuticals, Inc as of 2026-06-30, including Oaktree Capital Management, D.E. Shaw, Renaissance Technologies LLC, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Oaktree Capital Management | AMPHASTAR PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 37200800.00 USD | 40880000.000000 | Principal | add | Original filing |
| D.E. Shaw | AMPHASTAR PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 17900629.00 USD | 887048.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | AMPHASTAR PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 10596518.00 USD | 525100.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | AMPHASTAR PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 204605.00 USD | 10139.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.